Free Trial
→ Trump set to Boost Social Security Checks by 400%? (From InvestorPlace) (Ad)tc pixel
NASDAQ:NTHI

Neonc Technologies 8/18/2025 Earnings Report

Neonc Technologies logo
$10.49 +0.73 (+7.48%)
As of 09/12/2025 04:00 PM Eastern
ProfileEarnings History

Neonc Technologies EPS Results

Actual EPS
-$0.30
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Neonc Technologies Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Neonc Technologies Announcement Details

Quarter
Date
8/18/2025
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Neonc Technologies Earnings Headlines

NeOnc Technologies Receives FDA Authorization to Proceed with Phase II Clinical Trial of NEO212 – A First-in-Class Oral Chemical Conjugated Chemotherapy Candidate for Brain ...
September 10, 2025  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/neonc-technologies-receives-fda-authorization-to-proceed-with-phase-ii-clinical-trial-of-neo212-a-first-in-class-oral-chemical-conjugated-chemotherapy-candidate-for-brain-cancer-1035132278
Blue Gold Appoints Quazar's Sameer Salgar to Advisory Board to Establish UAE Ties and Guide Digital Gold Strategy
September 10, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/09/10/3147865/0/en/blue-gold-appoints-quazar-s-sameer-salgar-to-advisory-board-to-establish-uae-ties-and-guide-digital-gold-strategy.html
Another gold high? Here’s the move Wall Street is missing …
Gold has surged past $3,600 an ounce, up 45% in the last year, but Weiss Ratings analyst Sean Brodrick says the real opportunity is in a little-known strategy that has historically outpaced gold’s rallies many times over — including one past run where investors saw gains of more than 26,000%.tc pixel
 |  Weiss Ratings (Ad)
NeOnc Technologies Receives FDA Authorization to Proceed with Phase II Clinical Trial of NEO212 – A First-in-Class Oral Chemical Conjugated Chemotherapy Candidate for Brain Cancer
September 10, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/09/10/3147781/0/en/neonc-technologies-receives-fda-authorization-to-proceed-with-phase-ii-clinical-trial-of-neo212-a-first-in-class-oral-chemical-conjugated-chemotherapy-candidate-for-brain-cancer.html
NeOnc closes strategic acquisition of advanced AI, 3D bioprinting IP
August 25, 2025  |  msn.comhttps://www.msn.com/en-us/money/technology/neonc-closes-strategic-acquisition-of-advanced-ai-3d-bioprinting-ip/ar-AA1LbKhl
NeOnc Technologies Closes Strategic Acquisition of Advanced AI and 3D Bioprinting IP, Appointing World-Renowned Scientist Dr. Ishwar K. Puri to its Board
August 25, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/08/25/3138504/0/en/neonc-technologies-closes-strategic-acquisition-of-advanced-ai-and-3d-bioprinting-ip-appointing-world-renowned-scientist-dr-ishwar-k-puri-to-its-board.html
See More Neonc Technologies Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Neonc Technologies? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Neonc Technologies and other key companies, straight to your email.

About Neonc Technologies

Neonc Technologies (NASDAQ:NTHI) develops novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. Its lead products in development include NEO100, which is in Phase 2a clinical trials for treating glioblastoma; and NEO212, a covalently conjugated molecule combining the chemotherapeutic drug temozolomide with perillyl alcohol that is completed preclinical testing. The company was incorporated in 2023 and is based in Los Angeles, California.

View Neonc Technologies Profile

More Earnings Resources from MarketBeat

Earnings Tools
Earnings By Country
Latest Articles